DefiniGEN is a spin-out from the University of Cambridge, creating highly predictive disease cell models for preclinical research and drug development. The process of bringing new drugs to market is arduous, expensive and blighted by a high failure rate. DefiniGEN’s models help the biopharma industry to respond to these challenges, enabling highly relevant information on potential new drug efficacy to be realised in an accelerated manner.
Our technology platform harnesses iPSC technology to develop models that are transformational for drug discovery. We have gained significant commercial momentum in recent years, and this investment will be a significant driver of continued growth for DefiniGEN. We’re thrilled to be working with BGF, who understand the complex issues that we are addressing and are committed to helping us accelerate the next phase of growth.Dr Marcus Yeo , CEO
Business funding insights
BGF explains: Is private equity the best way to fund an M&A growth strategy?
What to consider when seeking private equity funding for acquisitive growth, from investment timelines to deal types and more
BGF explains: what do private equity investors look for in a business?
We explain what private equity investors look for in the businesses they invest in, from your growth plan to your management team.